DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Quarter Results
Eckert & Ziegler: positive start to the year 2015
05.05.2015 / 07:45
---------------------------------------------------------------------
Press release
Eckert & Ziegler: positive start to the year 2015
Berlin, 05 May 2015. Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for isotope technology
applications in medicine, science and industry, saw double-digit percentage
increases in sales and earnings in the first quarter of 2015.
Sales rose by 11 % to EUR 34.0 million mainly due to currency effects. EBIT
climbed by a disproportionately high amount of EUR 1.8 million, or 59 %, to
EUR 4.8 million. This resulted in a 68 % rise in profit for the period to
EUR 2.7 million or EUR 0.51 per share.
The Isotope Products segment benefited the most from the weak euro, while
also recording a positive acquisition effect. This caused sales to rise by
10 % to EUR 16.0 million. However, these effects did not result in any
increase in profit, meaning that EBIT remained constant at EUR 3.7 million.
The Radiation Therapy segment fell short of average development in the past
year. However, the situation improved in the first quarter of 2015. Implant
sales rose organically, above and beyond currency effects. Afterloader
sales may have declined, but the recently obtained approval for the new
SagiNova(R) equipment offers potential for a major rise in sales here. Due
to restructuring measures and a positive currency effect, EBIT came in at
break even according to the 2015 plan.
The Radiopharma segment was the shining light of our business, recording
further sales growth in the equipment division and with the new gallium
generators. It also benefited from the currency effects. Figures even
exceeded the disproportionately strong first quarter of 2014 by a
considerable margin, with EBIT rising by 21 % to EUR 1.4 million.
The Others segment successfully reduced the loss in the waste disposal
division through price increases, while a rise in costs allocated to other
segments led to a break-even result at the holding company. All in all, the
segment's losses were cut by half year on year. EBIT increased by EUR 0.4
million to EUR -0.5 million.
Cash flow from operating activities was much improved year on year at EUR
0.6 million (first quarter of 2014: EUR1.7 million). However, cash flow
from operating activities was lower than the pleasing profit for the period
suggests. The main reasons for this were the reduction of liabilities and
provisions and the processing of advance payments. In addition, the profit
for the period includes non-cash income offsetting depreciation of EUR 1.5
million, which was largely attributable to currency effects.
In the 2015 fiscal year, sales of more than EUR 133 million are expected
and net profit will likely exceed the amount of EUR 1.71 per share.
The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz115e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str.
10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
---------------------------------------------------------------------
05.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich
End of News DGAP News-Service
---------------------------------------------------------------------
352607 05.05.2015
DGAP-News: Eckert & Ziegler: positive start to the year 2015
| Source: EQS Group AG